Full history for every metric is available with a Kvantra account
BBS-Bioactive Bone Substitutes Oyj (BONEH.HE)
Key financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | €m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | €m | -3 | -2 | |||||
| Net profit | €m | 0 | -2 | -3 | -3 | -3 | -3 | -2 |
| EPS reported | € | -0.29 | -0.12 | |||||
| Operating cashflow per share | € | -0.24 | -0.24 | |||||
| Capex per share | € | 0.00 | 0.00 | |||||
| FCF per share | € | -0.24 | -0.24 | |||||
| Free cash flow | €m | -3 | -1 | |||||
| Net debt | €m | 3 | 5 | |||||
| Book value equity | €m | 5 | 4 | |||||
| Book value per share | € | 0.42 | 0.18 | |||||
| Number of shares | m | 12.09 | 20.82 | |||||
| DPS (TTM paid) | € | 0.00 | 0.00 |
Financial summary
Financials in EUR| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.09 | 0.40 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -1.91 | -1.01 | |||||
| EV/EBITDA LTM | x | -2.66 | -3.70 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -62.39% | -535.59% | |||||
| FCF Yield | % | -52.35% | -99.30% | |||||
| Quality | ||||||||
| ROE | % | -68.20% | -74.29% | |||||
| ROIC | % | -33.54% | -33.54% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -0.61 | -0.27 | |||||
| Net Debt/EBITDA | x | -0.88 | -0.88 | |||||
| EBIT/Net interest | x | -28.78 | -28.78 | |||||
| Net debt/market cap | % | 49.83% | 314.64% | |||||
| Net debt/Equity | x | 0.54 | 1.25 | |||||
| Gross debt/equity | x | 0.93 | 1.47 | |||||
Company overview
BBS-Bioactive Bone Substitutes Oyj operates as a Finnish biomedical technology firm, dedicated to innovating, manufacturing, and commercializing bioactive medical devices and implants for orthopedic surgical applications. The company's key offering, ARTEBONE, is an orthobiological product composed of tricalcium phosphate and a comprehensive spectrum of natural bone proteins. This solution is predominantly used for addressing bone deficiencies and aiding healing processes, especially in extremities such as the foot and ankle. BBS-Bioactive Bone Substitutes Plc commenced operations in 1991 and has its corporate headquarters situated in Oulu, Finland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
BBS-Bioactive Bone Substitutes Oyj (BONEH.HE)
BBS-Bioactive Bone Substitutes Oyj operates as a Finnish biomedical technology firm, dedicated to innovating, manufacturing, and commercializing bioactive medical devices and implants for orthopedic surgical applications. The company's key offering, ARTEBONE, is an orthobiological product composed of tricalcium phosphate and a comprehensive spectrum of natural bone proteins. This solution is predominantly used for addressing bone deficiencies and aiding healing processes, especially in extremities such as the foot and ankle. BBS-Bioactive Bone Substitutes Plc commenced operations in 1991 and has its corporate headquarters situated in Oulu, Finland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free